search

Active clinical trials for "Lymphoma"

Results 2881-2890 of 5971

A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab

Malignant Solid TumorLymphoma

This is a dose escalation protocol to determine the feasibility of co-administration of RRx-001 and nivolumab. Immune surveillance is an endogenous mechanism to cause remission of neoplastic growth. Epigenetic agents like RRx-001 are associated not only with enhanced gene transcription and restored expression of silenced genes but also with increased expression of pro-inflammatory mediators, upregulation of PD-L1 on tumor cells and de-repression of antigens that promote immune recognition of tumors. It is hypothesized that RRx-001, will prime or sensitize to immune checkpoint therapy targeting PD-1 interaction with nivolumab.

Completed12 enrollment criteria

Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid...

Metastatic MelanomaRecurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor21 more

This phase I/II trial studies the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas that have come back (recurrent) or do not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether nivolumab works better alone or with ipilimumab in treating patients with recurrent or refractory solid tumors or sarcomas.

Completed71 enrollment criteria

A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination...

LymphomaLeukemia3 more

This study is designed to determine the recommended phase 2 dose (RP2D), and the safety, and efficacy of durvalumab as monotherapy and when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and rituximab at the RP2D in adults with lymphoma or chronic lymphocytic leukemia (CLL).

Completed20 enrollment criteria

"MIRO" Molecularly Oriented Immuno-radio-therapy

Follicular LymphomaGrade 13 more

Phase II prospective multicenter study for stage I/II Follicular Lymphoma treated with involved-field radiotherapy (IFRT) at doses of 24 Gy) with or without Ofatumumab for 8 weekly doses on molecular basis. Patients with positive basal Bcl-2 will be followed every 3 months and with Bcl-2 detection every 6 months for 3 years. Patient with negative basal Bcl-2 will be followed every 3 months without further Bcl-2 detection. Ofatumumab treatment will be administered to: Patients with positive basal PCR for Bcl-2-IgH rearrangement in BM and/or PB, resulting still positive after IFRT; Patients with positive basal PCR for Bcl-2-IgH in

Completed35 enrollment criteria

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory...

Diffuse Large B-Cell LymphomaFollicular Lymphoma

The purpose of this study is to evaluate the efficacy, safety and tolerability of the combination treatment of ibrutinib and MEDI4736 in subjects with relapsed or refractory lymphomas.

Completed14 enrollment criteria

Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP...

Diffuse Large B-cell Lymphoma

The purpose of the Phase I of the study is to evaluate the safety and the maximum-tolerated dose (MTD) of the combination R-ESHAP with lenalidomide as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma The purpose of the Phase II of the study is to evaluate ORR of LR-ESHAP in patients with relapsed or refractory DLBCL candidates to HDT and ASCT

Completed32 enrollment criteria

Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours...

Recurrent LymphomaRefractory Lymphoma2 more

The purpose of this study is to determine the best dose of vinblastine that can be given with a new drug, temsirolimus.

Completed70 enrollment criteria

Phase III Copanlisib in Rituximab-refractory iNHL

LymphomaNon-Hodgkin

To assess the safety of copanlisib.

Completed28 enrollment criteria

Nivolumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or High-Risk Untreated Chronic...

Loss of Chromosome 17pRecurrent Chronic Lymphocytic Leukemia4 more

This phase II trial studies how well nivolumab and ibrutinib work when given together in treating patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, or Richter transformation that has come back after a period of improvement (relapsed), does not respond to treatment (refractory), or is at high risk of spreading and has not been treated. Immunotherapy with monoclonal antibodies, such as niolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving nivolumab together with ibrutinib may kill more cancer cells.

Completed27 enrollment criteria

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)...

Non-Hodgkin LymphomaBurkitt's Lymphoma12 more

This study evaluates ADCT-402 in participants with Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL). Participants will participate in a dose escalation phase (Part 1) and dose expansion (Part 2). In Part 2, participants will receive the dose level identified in Part 1.

Completed31 enrollment criteria
1...288289290...598

Need Help? Contact our team!


We'll reach out to this number within 24 hrs